SARS-CoV-2 variants and ending the COVID-19 pandemic

Fontanet, Arnaud; Autran, Brigitte; Lina, Bruno; Kiény, Marie Paule; Karim, Salim Safurdeen. Abdool; Sridhar, Devi

doi:10.1016/s0140-6736(21)00370-6

Cited by 503 publications

(490 citation statements)

References 17 publications

Supporting

Mentioning

478

Contrasting

Unclassified

Order By: Relevance

“…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological cause of Coronavirus Disease 19 (COVID-19) is responsible for the most severe pandemic outbreak of the current century [1]. Naturally, it is the object of unprecedented scientific scrutiny, with more than 800,000 SARS-CoV-2 genomic sequences having been generated and publicly shared since December 2019.…”

Section: Introductionmentioning

confidence: 99%

Preliminary report on SARS-CoV-2 Spike mutation T478K

Giacomo

Mercatelli

Рахимов

et al. 2021

Preprint

View full text Add to dashboard Cite

Several SARS-CoV-2 variants have emerged, posing a renewed threat to COVID-19 containment and to vaccine and drug efficacy. In this study, we analyzed more than 820,000 SARS-CoV-2 genomic sequences deposited up to March 26, 2021 and identified a novel T478K mutation located on the SARS-CoV-2 Spike protein. The mutation is structurally located in the region of interaction with human receptor ACE2 and was detected in 4,214 distinct cases. We show that T478K has appeared and risen in frequency since January 2021, predominantly in Mexico and North America, but we could also detect it in several European countries.

show abstract

Section: Introductionmentioning

confidence: 99%

Preliminary report on SARS-CoV-2 Spike mutation T478K

Giacomo

Mercatelli

Рахимов

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…This is further supported by our analysis of 71 soluble cytokines and chemokines in the blood of patients with SARS-CoV-2, Flu, or RSV. The recent identification of novel SARS-CoV-2 variants that may increase transmission and alter vaccine efficacy 70 underscores the need for continued development of treatment strategies specifically for severe COVID-19 disease course. Thus, we speculate that the overlapping immune landscapes in SARS-CoV-2, Flu, and RSV infections could be leveraged to identify and hasten common treatment strategies that could be leveraged for the response to the next pandemic respiratory virus.…”

Section: Discussionmentioning

confidence: 99%

A differential regulatory T cell signature distinguishes the immune landscape of COVID-19 hospitalized patients from those hospitalized with other respiratory viral infections

Vick

Frutoso

Mair

et al. 2021

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 infection has caused a lasting global pandemic costing millions of lives and untold additional costs. Understanding the immune response to SARS-CoV-2 has been one of the main challenges in the past year in order to decipher mechanisms of host responses and interpret disease pathogenesis. Comparatively little is known in regard to how the immune response against SARS-CoV-2 differs from other respiratory infections. In our study, we compare the peripheral blood immune signature from SARS-CoV-2 infected patients to patients hospitalized pre-pandemic with Influenza Virus or Respiratory Syncytial Virus (RSV). Our in-depth profiling indicates that the immune landscape in patients infected by SARS-CoV-2 is largely similar to patients hospitalized with Flu or RSV. Similarly, serum cytokine and chemokine expression patterns were largely overlapping. Unique to patients infected with SARS-CoV-2 who had the most critical clinical disease state were changes in the regulatory T cell (Treg) compartment. A Treg signature including increased frequency, activation status, and migration markers was correlated with the severity of COVID-19 disease. These findings are particularly relevant as Tregs are being discussed as a therapy to combat the severe inflammation seen in COVID-19 patients. Likewise, having defined the overlapping immune landscapes in SARS-CoV-2, existing knowledge of Flu and RSV infections could be leveraged to identify common treatment strategies.

show abstract

“…Despite this, in these unprecedented times, it is impossible to answer how and when the history of COVID-19 will end, further studies are needed to better understand the longterm effects of COVID-19 infection during the critical phases of development in the risk to the development of cardiometabolic diseases, as well as to plan and decrease the cost of treatments for COVID-19 consequences. Despite the vaccination program that is occurring worldwide, that this disease still affects populations and causes outbreaks in all countries together with the fact that new variants of SARS-CoV-2 are emerging has brought about new doubts about future consequences (Fontanet et al, 2021). Taken together, the hypothesis approached in the current study has high relevance and can help us to understand the importance to create preventive methodologies to avoid the possible increase of NCD and health public spending due to future consequences of COVID-19.…”

Section: Future Directionsmentioning

confidence: 99%

COVID-19 During Development: A Matter of Concern

Saavedra

Prates

Gonçalves

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

A new infectious disease, COVID-19, has spread around the world. The most common symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are cough and fever, but severe cases can develop acute respiratory distress syndrome. The main receptor for SARS-CoV-2 in human tissue is angiotensin-converting enzyme 2, and the lungs, heart, and kidneys are the most affected organs. Besides the inflammatory process and tissue damage, the presence of a cytokine “storm” has been related to a higher mortality rate. Other infectious viral diseases, such as Zika, chikungunya, and influenza, were associated with complications in pregnant women, such as growth restriction, malformation, preterm birth, low birth weight, miscarriage, and death, although they can also cause developmental disorders in infants and adolescents. Evidence points out that stressors during pregnancy and infancy may lead to the development of obesity, diabetes, and cardiovascular disease. Therefore, we hypothesize that COVID-19 infection during the critical phases of development can program the individual to chronic diseases in adulthood. It is important that COVID-19 patients receive proper monitoring as a way to avoid expensive costs to public health in the future.

show abstract

SARS-CoV-2 variants and ending the COVID-19 pandemic

Cited by 503 publications

References 17 publications

Preliminary report on SARS-CoV-2 Spike mutation T478K

Preliminary report on SARS-CoV-2 Spike mutation T478K

A differential regulatory T cell signature distinguishes the immune landscape of COVID-19 hospitalized patients from those hospitalized with other respiratory viral infections

COVID-19 During Development: A Matter of Concern

Contact Info

Product

Resources

About